Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06596291 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

A Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity, sponsored by EG 427.

Recruiting
Registry status
Phase 1
Development phase
16
Enrollment target
4
Study locations

NCT06596291 is a Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity that is actively recruiting participants, run by EG 427. The registered enrollment target is 16 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06596291, a Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity, is actively recruiting participants, sponsored by EG 427.

RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target
4
Study locations

Study Summary

This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.

Conditions Studied

Spinal Cord Injuries Neurogenic Detrusor Overactivity

Interventions

  • DRUG EG110A

Study Locations (4)

California

  • Rancho Los Amigos National Rehabilitation Center - Downey

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

Pennsylvania

  • Sidney Kimmel Medical College - Philadelphia

Texas

  • UTHealth Houston / TIRR Memorial Hermann - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-01-08
Est. Completion 2027-06
Phase Phase 1

Sponsor

EG 427

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06596291

The ClinicalTrials.gov registry entry for NCT06596291 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (74% lower). The listed sponsor is EG 427, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which EG110A is the first listed.

NCT06596291 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Michigan, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06596291 about?

NCT06596291 is a clinical study titled "Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization". This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), w...

What is the current status of trial NCT06596291?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-01-08. Estimated completion is 2027-06.

What conditions does trial NCT06596291 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Neurogenic Detrusor Overactivity.

What interventions are being tested in trial NCT06596291?

The interventions under investigation include: EG110A (DRUG).

Who is sponsoring clinical trial NCT06596291?

This trial is sponsored by EG 427, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06596291 being conducted?

This trial has 4 study locations across California, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Cord Injuries

All registered trials for this condition

Neurogenic Detrusor Overactivity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.